Hogan Lovells is representing Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of obesity, in filing for voluntary relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
Orexigen also intends to file a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code. Details of the proposed bidding procedures can be found in the company press release.
Orexigen Therapeutics Inc. is a biopharmaceutical company. The Company, led by Michael A Narachi, Monica Forbes and Thomas Cannell, is focused on the development and commercialization of pharmaceutical products for the treatment of the central nervous system (CNS) disorders with an initial focus on obesity. In 2017 Orexigen recorded $33 Million Revenues.
The team representing Orexigen is led by Hogan Lovells Business Restructuring and Insolvency practice group head and partner Chris Donoho (Picture), counsel Christopher Bryant and senior associate John Beck. The team also consisted of associates Sean Feener and Eric Einhorn.
Law Firms: Hogan Lovells;
Clients: Orexigen Therapeutics Inc. ;